All In Biotech

Drug Trial Radar · NCT00373334

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

A Double-Blind, Randomized, Parallel, Multicenter Study of Axid (Nizatidine) Oral Solution in the Treatment of Gastroesophageal Reflux Disease (GERD) Symptoms in Infants Age 30 Days-1 Year

Last checked: Nov 20, 2026Latest source record: Nov 18, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

138

Actual

Start

Aug 2006

Primary completion

Feb 2008

Study completion Feb 2008

Sponsor

Lead sponsor
Braintree LaboratoriesIndustry
Sponsor type
Industry
First posted
Sep 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 days, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.

Conditions

  • Gastroesophageal Reflux Disease
  • GERD
  • Heartburn

Interventions

  • nizatidine (axid)Drug

    nizatidine (axid)

  • nizatidine (axid)Drug

    nizatidine (axid)

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) SuccessTime frame: 8 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Searcy, Arkansas

  • Site not named

    Madiera, California

  • Site not named

    Centennial, Colorado

  • Site not named

    Orlando, Florida

  • Site not named

    Panama City, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tifton, Georgia

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Bismarck, North Dakota

  • Site not named

    Fargo, North Dakota

  • Site not named

    Fairfield, Ohio

  • Site not named

    Mason, Ohio

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Clarksville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Missouri City, Texas

  • Site not named

    Temple, Texas

  • Site not named

    Ogden, Utah

  • Site not named

    South Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.